Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ALPL | P05186 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960104 | 0.85 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1L3MBTL1POLBKMT2A | |
| SCHEMBL1169297 | 0.81 | NAMPT (0.72) | SMN1; SMN2ALDH1A1PKMNAMPT | |
| SCHEMBL7425436 | 0.81 | PKM (0.82) | SMN1; SMN2ALDH1A1KMT2APKMNAMPT | |
| SCHEMBL18315951 | 0.80 | NAMPT (0.80) | SMN1; SMN2L3MBTL1NAMPT | |
| SCHEMBL5960082 | 0.80 | ALDH1A1 (0.75) | SMN1; SMN2ALDH1A1L3MBTL1POLBKMT2A | |
| SCHEMBL13539338 | 0.79 | ALPL (1.00) | ALDH1A1ALPL | |
| SCHEMBL13660785 | 0.78 | TSHR (0.69) | SMN1; SMN2ALDH1A1POLBKMT2APKM | |
| SCHEMBL5960118 | 0.78 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1L3MBTL1POLBKMT2A | |
| SCHEMBL5960079 | 0.78 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL858645 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010111653-A2 | MODULATING IRES-MEDIATED TRANSLATION | THE UAB RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | EIF2AK2, EIF4EBP1, EIF4E | SMN1; SMN2 1695/4885ALDH1A1 4020/4885L3MBTL1 477/4885 |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | EIF2AK2, RPS25, RPL35 | SMN1; SMN2 1417/4885ALDH1A1 3556/4885L3MBTL1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.